Substance / Medication

Telotristat ethyl

Overview

Active Ingredient
telotristat ethyl
RxNorm CUI
1872441

Indications

Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Labeler: Lexicon Pharmaceuticals, Inc.Updated: 2025-10-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes Amy, Pashley Alex, Feuilly Marion et al. · Neuroendocrinology · 2021
PMID: 32097914Meta-Analysis
Management of carcinoid syndrome: a systematic review and meta-analysis.
Hofland Johannes, Herrera-Martínez Aura D, Zandee Wouter T et al. · Endocr Relat Cancer · 2019
PMID: 30608900Meta-Analysis
Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Wolin Edward M, Benson Iii Al Bowen · Oncology · 2019
PMID: 31018209Meta-Analysis
Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour Nicole, Sawh Sonja C · Can J Anaesth · 2013
PMID: 23328959Meta-Analysis
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Dillon Joseph S, Kulke Matthew H, Hörsch Dieter et al. · J Gastrointest Cancer · 2021
PMID: 32146619TrialFull text (PMC)
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel Marianne, Gross David J, Benavent Marta et al. · Endocr Relat Cancer · 2018
PMID: 29330194TrialFull text (PMC)
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert Martin O, Kaltsas Gregory, Hörsch Dieter et al. · Clin Ther · 2018
PMID: 29724499Trial
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke Matthew H, Hörsch Dieter, Caplin Martyn E et al. · J Clin Oncol · 2017
PMID: 27918724Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Telotristat ethyl (substance)
SNOMED CT
733879005
UMLS CUI
C4317559
RxNorm CUI
1872441
Labeler
Lexicon Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.